Cancer is a global challenge, impacting lives and families in countless ways.

Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs. A Toronto-based company established in 2013, with U.S. headquarters in Dallas, Texas, Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further its mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.

Perimeter envisions a world where patients no longer experience the emotional and physical trauma of a second operation due to cancer left behind.

The Re-Excision Challenge

Surgeons have worked tirelessly to solve for intraoperative margin assessment, with the ultimate goal of improving survivability and quality of life. Yet, it still remains one of their most pressing problems, recognized by professional societies as the “re-excision epidemic.”

Traditional imaging used in the operating room does not have the resolution to detect microscopic cancer cells, and Pathology must be used after surgery to confirm clean margins, which takes up to a week.

If margins are positive, patients typically return for another surgery, impacting them physically, emotionally and financially, delaying adjunct treatments and getting back to their lives.

Even for skilled surgeons using the latest techniques, the odds of needing a repeat surgery are relatively high—nearly 1 in 4 for some types of cancer:

23% of breast lumpectomies require re-excision4
11.5% of thyroid cancers have a positive margin5
21% of prostate cancers have a positive margin5

A Game Changer for Margin Visualization

Perimeter’s proprietary Optical Coherence Tomography (OCT) technology provides high-definition, 3d images of margins in the operating room. This has the potential to give surgeons clarity on margin status so they can take more tissue at the point of care, not days later when pathology reports come back.

Optical Coherence Tomography (OCT), developed out of MIT in 1991, can give surgeons the resolution to help visualize hard-to-detect tissue microstructures associated with early-stage cancers.

Simply put, we provide advanced margin imaging in the moment – when it matters most.

You Might Be Interested In

Leadership Team


News & Events

Connect with Us

Get in Touch